Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: A novel approach for immunotherapy

被引:35
作者
Hamel, Y
Blake, N
Gabrielsson, S
Haigh, T
Jooss, K
Martinache, C
Caillat-Zucman, S
Rickinson, AB
Hacein-Bey, S
Fischer, A
Cavazzana-Calvo, M
机构
[1] Hop Necker Enfants Malad, INSERM, U429, F-75743 Paris 15, France
[2] Univ Birmingham, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England
[3] Inst Curie, F-75005 Paris, France
[4] Genethon, F-91000 Evry, France
[5] Hop Necker Enfants Malad, Lab Therapie Cellulaire & Genique, F-75743 Paris 15, France
[6] Hop Necker Enfants Malad, Lab Histocompatibil, F-75743 Paris 15, France
关键词
D O I
10.1089/10430340252899028
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus (Ad) cause significant morbidity and mortality in immunocompromised patients undergoing allogeneic stem cell transplantation. We have established a procedure to generate polyclonal cytotoxic T lymphocyte (CTL) populations with specificity against Ad and CMV or against Ad and EBV. Healthy donor-derived dendritic cells (DCs) were transduced with recombinant adenovirus encoding either CMV pp65 or EBV EBNA3C and used to stimulate autologous T cells. Stimulated T lymphocytes displayed specific simultaneous cytotoxicity against CMV and adenovirus and to a lesser extent against adenovirus and EBV. Recombinant vaccinia virus encoding individual adenovirus proteins showed that the T cell response to the adenovirus was directed mainly against the capsid protein hexon. The frequency of IFN-gamma-secreting T cells was 0.02% for adenovirus alone, and 0.05 and 0.14% for adenoviruses encoding EBNA3C and pp65, respectively. pp65-specific CTLs killed autologous fibroblasts infected with the laboratory strain CMV AD169. The culture conditions were specific as alloreactive T cells were not expanded. Therefore, this approach could be considered in order to generate efficient virus cytolytic T cells to be used as adoptive immunotherapy in transplanted patients.
引用
收藏
页码:855 / 866
页数:12
相关论文
共 46 条
[1]   Incoming human cytomegalovirus pp65 (UL83) contained in apoptotic infected fibroblasts is cross-presented to CD8+ T cells by dendritic cells [J].
Arrode, G ;
Boccaccio, C ;
Lule, J ;
Allart, S ;
Moinard, N ;
Abastado, JP ;
Alam, A ;
Davrinche, C .
JOURNAL OF VIROLOGY, 2000, 74 (21) :10018-10024
[2]  
Arthur JF, 1997, CANCER GENE THER, V4, P17
[3]   PHYLOGENETIC-RELATIONSHIPS AMONG ADENOVIRUS SEROTYPES [J].
BAILEY, A ;
MAUTNER, V .
VIROLOGY, 1994, 205 (02) :438-452
[4]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[5]   Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood [J].
Bender, A ;
Sapp, M ;
Schuler, G ;
Steinman, RM ;
Bhardwaj, N .
JOURNAL OF IMMUNOLOGICAL METHODS, 1996, 196 (02) :121-135
[6]   Human CD8+ T cell responses to EBV EBNA1:: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing [J].
Blake, N ;
Lee, S ;
Redchenko, I ;
Thomas, W ;
Steven, N ;
Leese, A ;
Steigerwald-Mullen, P ;
Kurilla, MG ;
Frappier, L ;
Rickinson, A .
IMMUNITY, 1997, 7 (06) :791-802
[7]   Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells [J].
Bonini, C ;
Lee, SP ;
Riddell, SR ;
Greenberg, PD .
JOURNAL OF IMMUNOLOGY, 2001, 166 (08) :5250-5257
[8]   Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation [J].
Broers, AEC ;
van der Holt, R ;
van Esser, JWJ ;
Gratama, JW ;
Henzen-Logmans, S ;
Kuenen-Boumeester, V ;
Löwenberg, B ;
Cornelissen, JJ .
BLOOD, 2000, 95 (07) :2240-2245
[9]  
Brossart P, 1997, J IMMUNOL, V158, P3270
[10]   Genetic predisposition to IDDM [J].
Caillat-Zucman, S ;
Bach, JF .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2000, 19 (03) :227-246